Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
HealthDay News – For treatment of retinopathy of prematurity (ROP), 0.004mg may be the lowest effective dose of bevacizumab, according to a study published online April 23 in JAMA Ophthalmology.
David K. Wallace, MD, from the Jaeb Center for Health Research in Tampa, Florida, and colleagues sought to find the lowest dose of intravitreous bevacizumab effective for severe ROP using data from 55 premature infants with type 1 ROP in one or both eyes who were enrolled in a masked, multicenter, dose de-escalation study (April 2017 to May 2019). Analysis included 4-week outcomes.
The researchers found that the mean birth weight was 664g, and the mean gestational age was 24.8 weeks. All eyes (13 of 13) receiving 0.016mg achieved a successful 4-week outcome, as did 9 of 9 eyes receiving 0.008mg, and nine of 10 eyes receiving 0.004mg. However, only 17 of 23 eyes (74%) achieved successful 4-week outcomes receiving 0.002mg.
“Further investigation is warranted to confirm effectiveness of very low-dose intravitreous bevacizumab and its effect on plasma vascular endothelial growth factor levels and peripheral retinal vascularization,” the authors write.
